AstraZeneca's Baxfendy wins EU panel backing for uncontrolled hypertension

• AstraZeneca’s Baxfendy (baxdrostat) received a recommendation for European Union approval from the European Medicines Agency’s human medicines committee.
• The recommendation covers adults with hypertension insufficiently controlled by at least two blood pressure medicines.
• If cleared, Baxfendy would become the EU’s first and only aldosterone synthase inhibitor.
• Already published results from Phase III trials BaxHTN and Bax24 showed meaningful blood pressure reductions in patients with uncontrolled or resistant hypertension.
• Baxfendy was generally well tolerated, with no unexpected safety findings. The drug is already approved in the U.S. and other countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.